Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check28 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check43 days agoChange DetectedThe webpage has updated its date listings, removing older dates and adding new ones for May 2025.SummaryDifference0.4%
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.